DK0384514T3 - Dobbeltvirkende tabletsammensætning - Google Patents

Dobbeltvirkende tabletsammensætning

Info

Publication number
DK0384514T3
DK0384514T3 DK90200313.6T DK90200313T DK0384514T3 DK 0384514 T3 DK0384514 T3 DK 0384514T3 DK 90200313 T DK90200313 T DK 90200313T DK 0384514 T3 DK0384514 T3 DK 0384514T3
Authority
DK
Denmark
Prior art keywords
tablet
active ingredient
dose
dual
action
Prior art date
Application number
DK90200313.6T
Other languages
English (en)
Inventor
Richard John Dansereau
Michael John Kane
Original Assignee
Norwich Eaton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwich Eaton Pharma filed Critical Norwich Eaton Pharma
Application granted granted Critical
Publication of DK0384514T3 publication Critical patent/DK0384514T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK90200313.6T 1989-02-21 1990-02-12 Dobbeltvirkende tabletsammensætning DK0384514T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/314,672 US5032406A (en) 1989-02-21 1989-02-21 Dual-action tablet

Publications (1)

Publication Number Publication Date
DK0384514T3 true DK0384514T3 (da) 1994-02-07

Family

ID=23220946

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90200313.6T DK0384514T3 (da) 1989-02-21 1990-02-12 Dobbeltvirkende tabletsammensætning

Country Status (15)

Country Link
US (1) US5032406A (da)
EP (1) EP0384514B1 (da)
JP (1) JP2895146B2 (da)
KR (1) KR0173115B1 (da)
AT (1) ATE97571T1 (da)
AU (1) AU632793B2 (da)
CA (1) CA2010037C (da)
DE (1) DE69004708T2 (da)
DK (1) DK0384514T3 (da)
ES (1) ES2060923T3 (da)
IE (1) IE63311B1 (da)
IL (1) IL93424A (da)
NZ (1) NZ232604A (da)
PH (1) PH27331A (da)
ZA (1) ZA901261B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
IE64128B1 (en) * 1990-02-26 1995-07-12 Byrne Rynne Holdings Ltd A pharmaceutical composition
US5284659A (en) * 1990-03-30 1994-02-08 Cherukuri Subraman R Encapsulated flavor with bioadhesive character in pressed mints and confections
US5158728A (en) * 1991-04-12 1992-10-27 Elizabeth-Hata International, Inc. Multi-layer medicinal tablet forming machine and method for using the same
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
ES2106818T3 (es) * 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
EP0550108B1 (en) * 1991-12-30 1998-03-18 Akzo Nobel N.V. Sustained release thyroactive composition
WO1993019741A1 (en) * 1992-03-31 1993-10-14 Benzon Pharma A/S A pharmaceutical formulation
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
IT1260505B (it) † 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5422122A (en) * 1992-08-04 1995-06-06 Eurand America, Incorporated Controlled release potassium chloride tablet
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5595759A (en) * 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
KR19980703526A (ko) * 1995-04-03 1998-11-05 나가야마오사무 수크랄페이트 함유 제제 조성물
US5759574A (en) * 1995-05-15 1998-06-02 Bothe; Steven T. Tel-tale-tablets
IT1276689B1 (it) * 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
KR19980077329A (ko) * 1997-04-18 1998-11-16 이범진 이중층 약물 함유 제어방출성 제제
US6143309A (en) * 1998-03-12 2000-11-07 Archimica (Florida), Inc. Delivery of hydroxy carboxylic acids
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6387381B2 (en) 1998-09-24 2002-05-14 Ez-Med Company Semi-moist oral delivery system
US6773716B2 (en) * 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
IT1313590B1 (it) * 1999-08-03 2002-09-09 Formenti Farmaceutici Spa Composizioni a rilascio controllato di acido acetilsalicilico.
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
CA2440641A1 (en) * 2001-03-13 2002-09-19 Anand R. Baichwal Chronotherapeutic dosage forms containing glucocorticosteroid
JP2002326961A (ja) * 2001-04-27 2002-11-15 Taiyo Kagaku Co Ltd 打錠用滑沢剤
US20030012820A1 (en) * 2001-06-12 2003-01-16 Upadhyay Ajay Hasmukhlal Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom
US20040213848A1 (en) * 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
WO2003086353A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
AU2003237807B2 (en) 2002-04-15 2008-10-23 Rb Health (Us) Llc Sustained release of guaifenesin combination drugs
DE10224108A1 (de) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
NZ545921A (en) * 2003-09-19 2009-09-25 Penwest Pharmaceuticals Co Delayed released dosage forms
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
CN1327838C (zh) * 2004-07-08 2007-07-25 北京科信必成医药科技发展有限公司 维生素c口腔崩解片及其制备方法
CN1297263C (zh) * 2004-10-25 2007-01-31 北京科信必成医药科技发展有限公司 葡萄糖酸钙口腔崩解片及其制备工艺
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin
US10668012B2 (en) * 2008-09-04 2020-06-02 Farnam Companies, Inc. Chewable sustained release formulations
TR201001903A2 (tr) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salımlı tiyokolşiklozit tablet.
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR101684797B1 (ko) * 2015-08-27 2016-12-08 오철환 개폐구조를 갖는 글루건
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN112472679A (zh) * 2020-12-02 2021-03-12 上海汉维生物医药科技有限公司 双释放片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL108838C (da) * 1956-03-27
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
US3388041A (en) * 1964-01-27 1968-06-11 Richardson Merrell Inc High dosage sustained release tablet
FR1545612A (fr) * 1967-06-15 1968-11-15 Dausse Lab Procédé de fabrication de comprimés
GB1276089A (en) * 1968-08-23 1972-06-01 Pfizer Ltd Pharmaceutical preparations
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
DE3113901A1 (de) * 1981-04-07 1982-10-28 Basf Ag, 6700 Ludwigshafen Wirkstoffzubereitung zur oralen applikation
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette

Also Published As

Publication number Publication date
NZ232604A (en) 1992-10-28
KR0173115B1 (ko) 1999-02-01
DE69004708D1 (de) 1994-01-05
DE69004708T2 (de) 1994-03-24
EP0384514B1 (en) 1993-11-24
KR900012606A (ko) 1990-09-01
IE63311B1 (en) 1995-04-05
CA2010037C (en) 1995-10-31
ES2060923T3 (es) 1994-12-01
CA2010037A1 (en) 1990-08-21
IE900629L (en) 1990-08-21
ATE97571T1 (de) 1993-12-15
EP0384514A3 (en) 1991-04-03
PH27331A (en) 1993-06-08
AU632793B2 (en) 1993-01-14
EP0384514A2 (en) 1990-08-29
IL93424A0 (en) 1990-11-29
IL93424A (en) 1994-02-27
US5032406A (en) 1991-07-16
JP2895146B2 (ja) 1999-05-24
AU4997090A (en) 1990-08-30
ZA901261B (en) 1990-11-28
JPH03200724A (ja) 1991-09-02

Similar Documents

Publication Publication Date Title
DK0384514T3 (da) Dobbeltvirkende tabletsammensætning
EP1382331B1 (en) A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
JP5170723B2 (ja) 活性薬剤の制御放出用錠剤
US4695591A (en) Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4461759A (en) Constant release rate solid oral dosage formulations of veropamil
HU228269B1 (en) Hydrophilic/lipophilic polymeric matrix dosage formulation
ES2051782T3 (es) Una composicion farmaceutica de liberacion lenta.
UY23804A1 (es) Procedimiento de preparacion de medicamentos en forma de comprimidos con liberacion retardada de sustancia activa.
MY136318A (en) Sustained-release tablet composition
WO2002087547A1 (en) An improved process for preparation of four-drug anti-tubercular fixed dose combination
US4521401A (en) Constant release rate solid oral dosage formulations of quinidine
US4521402A (en) Constant release rate solid oral dosage formulations of hydrazine
EP1490034B1 (en) Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions
EP0793485A1 (en) Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
KR20180101307A (ko) 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
DE68907091D1 (de) Scleroglucan und wirkstoff enthaltende pharmazeutische tabletten und kapselgranulate.
ZA200309212B (en) An improved process for preparation of four-drug anti-tubercular fixed dose combination.